The efficacy and safety of selenium supplementation versus placebo in the treatment of Graves' orbitopathy: A systematic review and meta‐analysis of randomised controlled trials
Pooled result · Clinical activity score (CAS)Result — go to the resultMD −1.27 95% CI −1.68 to −0.85Authors' conclusion
Selenium is effective in reducing CAS and improving the palpebral aperture and GO-QOL in patients with GO. Additionally, it is safe and has promising therapeutic implications. However, further research is needed to validate its long-term efficacy and safety.
Study context
- Population
- Patients with Graves' orbitopathy (GO)4 RCTs
- Comparison
- Selenium vs placebo
- Outcome
- Clinical activity score (CAS)
- Follow-up
- 6 months
Methodological details1684 records screened
- 1684 records screened
Pooled result
As reported in the abstract
MD
−1.27
95% CI −1.68 to −0.85
P < 0.0001
Seleniumvs Placebo
MD −1.27 (95% CI −1.68 to −0.85); P < 0.0001
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Total GO-QOL improvement · 6 months | 2.54 (1.69–3.81) | P < 0.00001 | |
| 0.20.5125Relative risk (log scale) |
| Outcome | MD (95% CI) | P value | |
|---|---|---|---|
| GO-QOL visual functioning score · 6 months | 10.84 (4.94–16.73) | P = 0.003 | |
| GO-QOL psychological functioning score · 6 months | 12.76 (8.51–17.00) | P < 0.00001 | |
| −1001020Difference (linear scale) |
Clinical activity score (CAS), total Graves' orbitopathy quality of life (GO-QOL), visual and psychological functioning scores · 12 months
- Significantly improved these outcomes at 12 months
Palpebral aperture · 6 months
- Significant decrease in palpebral aperture, MD (95% CI), p
- −1.49 (−2.90, −0.08), p = .04
Proptosis, soft tissue involvement, ocular motility
- No significant differences in proptosis, soft tissue involvement and ocular motility
Safety
- No significant difference in adverse effects
Original publication
The efficacy and safety of selenium supplementation versus placebo in the treatment of Graves' orbitopathy: A systematic review and meta‐analysis of randomised controlled trials. Clin Endocrinol (Oxf). Published 13 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →